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ABSTRACT
Introduction: The effectiveness of basal insulin
(BI) or glucagon-like peptide-1 receptor agonists
(GLP-1 RAs) in providing glycemic control in
patients with type 2 diabetes (T2D) in Japanese
routine practice is not well known. This real-
world observational study evaluated the proba-
bility of achieving glycemic control in Japanese
patients with T2D uncontrolled by oral antidi-
abetic drugs (OADs) who initiated BI or GLP-1
RA therapy.
Methods: Patients with T2D aged C 18 years
initiating BI or GLP-1 RA therapy following
treatment with OADs were selected from real-
world data (RWD) retrieved from a large elec-
tronic medical record database in Japan, using
data from 01 January 2010 to 30 June 2019.
Patients were required to have glycated hemo-
globin (HbA1c) C 7% within 90 days prior to
the first prescription of BI or GLP-1 RA. The
probability of reaching first HbA1c \ 7% was
assessed over a 24-month period in cohorts of
patients who initiated BI (n = 3477) or GLP-1
RA (n = 780) and in subcohorts by number of
OADs at baseline (1, 2, or C 3), HbA1c at base-
line (C 7 to\8%, C 8 to\9%, or C 9%), and
age (\65 or C 65 years).
Results: Mean (standard deviation) baseline
HbA1c was 9.4% (1.8%) and 8.8% (1.4%) in
patients initiating BI or GLP-1 RA therapy,
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respectively. The cumulative probability of
achieving glycemic control was 50.1% with BI
and 60.3% with GLP-1 RA therapy, respectively,
at 12 months, and 60.8% and 66.6%, respec-
tively, at 24 months. Quarterly (3-month inter-
vals) conditional probabilities of achieving
glycemic control decreased over time and were
\10% after 12 months. Patients with more
OADs or higher HbA1c at baseline had a lower
probability of achieving glycemic control.
Conclusion: Among Japanese patients with
T2D who initiated BI or GLP-1 RA therapy after
treatment with OADs, the probability of reach-
ing first glycemic control diminished over time.
Further therapy intensification is warranted in
patients who do not achieve glycemic control
within 6–12 months with BI or GLP-1 RA, par-
ticularly those with high HbA1c or taking
multiple OADs.
PLAIN LANGUAGE SUMMARY
Patients with type 2 diabetes (T2D) who are
taking oral antidiabetic drugs (OADs) but still
have high blood glucose often require
injectable drugs, such as basal insulin (BI) or
glucagon-like peptide-1 receptor agonists (GLP-
1 RAs). While BI and GLP-1 RAs have been
shown to be effective in controlled clinical tri-
als, it is unclear how well they improve blood
glucose in real-world routine practice. Here, we
report the results of an observational study that
used data retrieved from a large electronic
medical records database in Japan to explore
how well BI and GLP-1 RAs allow patients to
achieve glycemic control [glycated hemoglobin
(HbA1c)\ 7%].
In Japanese patients with T2D receiving
treatment with OADs and initiating BI or GLP-1
RA therapy, the probability of achieving gly-
cemic control in the first quarter (3 months)
after initiation was 20.3% with BI and 38.6%
with GLP-1 RA. Among those patients who had
not previously reached glycemic control, the
probability of achieving first glycemic control
declined over time, as evidenced in each
quarterly assessment, and it was\10% after the
first year. Patients who had higher HbA1c levels
or were taking multiple OADs were less likely to
achieve glycemic control compared with those
with lower HbA1c or taking fewer OADs. Our
findings suggest that patients who have not
achieved their glycemic goals within the first
6–12 months after starting BI or GLP-1 RA
therapy have a low likelihood of achieving their
target by maintaining the same therapy. For
such patients, intensification with additional
medication (e.g., combined BI and GLP-1 RA
therapy) should be considered early in
treatment.
Keywords: Basal insulin; GLP-1 RA; Real-world
evidence; Type 2 diabetes
Key Summary Points
Why carry out this study?
Although basal insulin (BI) and glucagon-
like peptide-1 receptor agonists (GLP-1
RAs) have demonstrated efficacy in
randomized controlled trials, it remains
unclear whether these agents, when used
individually, are sufficient to provide
glycemic control in patients with type 2
diabetes (T2D) in real-world practice.
Real-world evidence from patients with
T2D in the USA and UK suggests that
patients not achieving glycemic targets
within 6–12 months following initiation
of BI or GLP-1 RA therapy may benefit
from treatment intensification (options
include combined BI and GLP-1 RA and
basal-bolus regimens); however, the
relevance of these data to Japanese
patients is unknown.
This real-world observational study was
conducted to evaluate the probability of
achieving glycemic control in Japanese
patients with T2D uncontrolled on oral
antidiabetic drugs (OADs) alone who
initiate BI or GLP-1 RA therapy.
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What was learned from the study?
In Japanese patients with T2D
uncontrolled on OADs alone, the
conditional probability (percentage of
patients who achieved glycemic control
among those who had not previously
reached glycemic control) of reaching first
glycated hemoglobin (HbA1c)\ 7% was
20.3% with BI and 38.6% with GLP-1 RA
therapy in the first quarter (3-month
interval) after BI or GLP-1 RA initiation;
the conditional probability in each
subsequent quarter declined over time,
and it was\10% for both treatments after
the first year. Throughout the 2-year
follow-up period, subgroups of patients
who initiated BI or GLP-1 RA therapy with
HbA1c C 9% or who were taking C 3
OADs had a lower probability of achieving
glycemic control compared with those
with lower baseline HbA1c or fewer OADs.
Treatment intensification should be
considered for patients who have not
achieved glycemic goals within the first
6–12 months of initiating BI or GLP-1 RA
treatment.
Patients taking BI or GLP-1 RA
therapy who have higher baseline HbA1c
or who are taking multiple OADs are less
likely to be successful in achieving
adequate glycemic control after
intensification with single
injectable therapy.
There is a need for different intensification
strategies for those patients who are
taking multiple OADs or have high
baseline HbA1c.
INTRODUCTION
Type 2 diabetes (T2D) is a chronic disease
characterized by insulin resistance and pro-
gressive decline in b-cell function and insulin
secretion, resulting in hyperglycemia [1, 2].
Persistent hyperglycemia is associated with an
increased risk of microvascular complications,
such as neuropathy, retinopathy, and
nephropathy; therefore, attaining ongoing gly-
cemic control is critical to T2D management
[3, 4]. In standard clinical practice, glycemic
control is assessed using glycated hemoglobin
(HbA1c) levels, and HbA1c\7% has become an
accepted therapeutic target based on the
reduced risk of diabetic complications in
patients achieving this target [5–7].
Current guidelines, including those set forth
by the American Diabetes Association (ADA),
European Association for the Study of Diabetes
(EASD), and Japan Diabetes Society (JDS), rec-
ommend stepwise treatment approaches to help
patients achieve and maintain glycemic control
[5, 6]. In patients whose glycemic levels are
inadequately controlled on oral antidiabetic
drugs (OADs), escalation to injectable therapy is
required. Current JDS guidelines recommend
that initial injectable therapies should focus on
basal insulin (BI) or glucagon-like peptide-1
receptor agonists (GLP-1 RAs). In the 2018 ADA/
EASD consensus report, GLP-1 RAs are recom-
mended as the first injectable for managing T2D
for most patients [5]. Combination therapy
with both BI and GLP-1 RAs is an option for
patients who do not achieve glycemic control
on either agent alone [5, 6].
The efficacy and safety of BI and GLP-1 RAs
have been well established in randomized con-
trolled trials (RCTs) [8–11]; however, in real-
world practice, monotherapy with either agent
may be insufficient to provide glycemic control
in many patients with T2D. A retrospective,
observational study found that among patients
in the USA initiating BI therapy following
OADs, the cumulative probability of reaching
glycemic control (HbA1c\7%) was 38% in the
first year and only increased by a further 8% in
the second year [12]. Similar trends were
observed in a UK-based retrospective database
study of patients initiating BI or GLP-1 RA
therapy, with the cumulative probability of
reaching HbA1c\7% within 12 months being
18% with BI and 30% with GLP-1 RA therapy,
with a low rate of increase over the second year
(11% and 12%, respectively) [13]. These studies
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suggest that intensification should be consid-
ered for patients not achieving glycemic control
within 6–12 months of BI or GLP-1 RA initia-
tion, and highlight the need for treatment
approaches that allow more patients to achieve
glycemic goals [12, 13]. However, it is not
known whether lessons from these data are
applicable outside of the USA or UK.
Here, we report the results of our real-world
observational study, which evaluated the prob-
ability of achieving glycemic control in Japa-
nese patients with T2D uncontrolled by oral
antidiabetic drugs (OADs) who initiated BI or
GLP-1 RA therapy, using data retrieved from a
large electronic medical record (EMR) database
in Japan. We also investigated the association
between glycemic control and patient baseline
characteristics, including number of OADs and
baseline HbA1c.
METHODS
Study Design and Cohort Construction
This was a population-based, retrospective,
observational cohort study using the RWD data-
base maintained by the Health, Clinic, and Edu-
cation Information Evaluation Institute (HCEI;
Kyoto, Japan) with support from RealWorld Data,
Co., Ltd. (Kyoto, Japan). The HCEI authorized the
use of data for the current study. This database
has collected EMRs of about 20 million patients
from approximately 160 medical institutions
across Japan since 2000, and includes information
on patient demographics, diagnoses, prescrip-
tions, procedures, and laboratory results from
both outpatient and inpatient services. Data were
automatically extracted from EMRs at each med-
ical institution and anonymized using unique
identifiers for each patient.
Data in the EMRs from 01 January 2010 to 30
June 2019 were used for this analysis. Patients
were included in the study cohort if they had a
confirmed diagnosis of T2D and had initiated BI
or GLP-1 RA therapy following treatment with
OADs. The date of first prescription of BI or
GLP-1 RA was defined as the index date. Full
inclusion criteria were: (1) diagnosis of T2D
identified using ICD-10 [10th revision of the
International Statistical Classification of Dis-
eases and Related Health Problems (ICD)] codes;
(2) at least one prescription for an OAD before
initiation of BI or GLP-1 RA therapy; (3) at least
one prescription of BI or GLP-1 RA; (4) intensi-
fication from OAD to BI or GLP-1 RA (first
antidiabetic medication was not a BI or GLP-1
RA); (5) at least one HbA1c measurement C 7%
within 90 days prior to and including the index
date; (6) at least one HbA1c measurement
within 720 days after the initiation date of BI or
GLP-1 RA therapy; (7) at least 180 days of
recorded medical history prior to the index date
(baseline period), during which no insulin or
GLP-1 RA was prescribed; (8) age C 18 years on
the index date; and (9) study entrance at least
720 days prior to the data cutoff date to ensure
up to 720 days of follow-up. Exclusion criteria
were: (1) ICD-10/Japanese disease codes for type
1 diabetes, gestational diabetes, or polycystic
ovarian syndrome; (2) an index date and end
date (last date of BI or GLP-1 RA prescription)
within 30 days; and (3) initiation of BI and GLP-
1 RA therapies on the same date (same index
date) or the addition of one medication within
3 months of the index date of the other medi-
cation (i.e., initiated BI and added a GLP-1 RA
within 3 months of initiation of BI, or vice
versa).
The patient selection process was designed
based on the original objective of the study,
which was to assess glycemic control in patients
who initiated BI or GLP-1 RA (without sequen-
tial therapy with the other agent) and in those
who received sequential therapy with BI and
GLP-1 RA (added BI to GLP-1 RA, or vice versa).
As the number of patients with records of
sequential therapy was low, the cohorts of
patients with sequential therapy were excluded
from the present analyses. Therefore, the main
study cohorts in this study consisted of patients
who initiated BI or GLP-1 RA, without sequen-
tial therapy.
Within the study cohorts of patients initiat-
ing BI or GLP-1 RA (without sequential ther-
apy), subcohorts of patients were constructed
based on: (1) the number of OADs taken at
baseline (1, 2, or C 3 OADs); (2) the last HbA1c
value prior to and up to the BI or GLP-1 RA
initiation date (7 to \8%, 8 to \9%, and
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C 9%); and (3) age on index date (\65 or
C 65 years).
This study was approved by the Research
Institute of Healthcare Data Science (RIHD)
ethics committee (No. RI2019005). This article
is based on an existing EMR database and does
not contain any studies with human partici-
pants or animals. The manuscript was prepared
in line with the STrengthening the Reporting of
OBservational studies in Epidemiology
(STROBE) guidelines [14].
Outcome Measures
Baseline characteristics and glycemic outcomes
were analyzed in the cohorts of patients initi-
ating BI or GLP-1 RA (without sequential ther-
apy). Glycemic control was determined by
change in HbA1c over time and cumulative
probability of reaching glycemic control (HbA1c
\7%) over 720 days post index date. Other
outcome measures included the time to first
reaching glycemic control and the conditional
probability of reaching glycemic control during
each quarter (3-month interval) post index date.
The cumulative probability of reaching gly-
cemic control was also analyzed in the subco-
horts of patients stratified by number of OADs
used at baseline, HbA1c at baseline, and age on
index date.
Statistical Approach
Baseline characteristics and change in HbA1c
over time from baseline were analyzed using
descriptive statistics. The period used to collect
baseline characteristics was over 180 days prior
to and up to the index date. The baseline HbA1c
value was defined as the last observation within
90 days prior to and including the index date.
The conditional probability of reaching gly-
cemic control was estimated quarterly (3-month
intervals post index date) as the proportion of
patients reaching first HbA1c\7% within the
specific quarter, among those patients who had
not previously achieved glycemic control and
were still taking BI or GLP-1 RA therapy and who
had at least one valid HbA1c measurement in
that quarter. The cumulative probability of
reaching first glycemic control over time was
estimated using the Kaplan–Meier method, and
log-rank tests were used for comparison between
subcohort categories. A P value of \ 0.05 was
considered to indicate statistical significance.
Patient data were censored at the end of BI or
GLP-1 RA prescription, or when the patient was
switched to a new non-BI or non-GLP-1 RA regi-
men or other insulin therapy. Records of HbA1c
\4% or[15% were removed.
RESULTS
Patient Cohort Selection
A total of 4356 patients initiating BI or GLP-1
RA therapy following OAD treatment were
identified from the EMR database (Fig. 1).
Among these patients, 58 and 41 patients,
respectively, had records of sequential therapy
with BI followed by GLP-1 RA add-on, or GLP-1
RA followed by BI add-on, and were excluded
from the analysis. The final analysis cohorts
included 3477 patients who initiated BI and did
not receive sequential therapy with GLP-1 RA
(BI cohort), and 780 patients who initiated GLP-
1 RA and did not receive sequential therapy
with BI (GLP-1 RA cohort).
Median and range of follow-up time (time
between index date and end date of BI or GLP-1
RA prescription) for the study cohorts and sub-
cohorts are shown in Table 1 and Electronic
Supplementary Material (ESM) Tables S1 and S2.
Baseline Characteristics
Patient demographics and baseline clinical
characteristics of all the study cohorts (whole
T2D, BI, and GLP-1 RA) are described in Table 1.
BIs and GLP-1 RAs identified in the study are
listed in ESM Table S3.
Patients initiating therapy with GLP-1 RA
were younger than those initiating BI therapy
(median age: 60.5 vs. 65.4 years, respectively).
Patients who initiated BI had higher baseline
HbA1c than those who initiated GLP-1 RA
[mean (standard deviation, SD): 9.4% (1.8%) vs.
8.8% (1.4%), respectively]. Patients in the GLP-1
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RA cohort appeared to have a higher body mass
index (BMI) than those in the BI cohorts (mean:
28.2 vs. 24.1 kg/m2, respectively). Regarding
common comorbidities, hypertension, dyslipi-
demia, and obesity were more common in the
GLP-1 RA cohort than in the BI cohort (hyper-
tension: 73.2 vs. 63.9%, respectively; dyslipi-
demia: 77.3 vs. 65.2%, respectively; obesity:
14.2 vs. 4.2%, respectively). Over one third of
patients in the BI and GLP-1 RA cohorts were
taking C 3 OADs. Higher percentages of patients
in the BI cohort compared with the GLP-1 RA
cohort were taking sulfonylureas (62.2 vs.
54.9%, respectively) or alpha-glucosidase inhi-
bitors (34.7 vs. 24.2%, respectively). A higher
percentage of patients in the GLP-1 RA cohort
versus the BI cohort were taking metformin
(56.3 vs. 38.9%, respectively), a dipeptidyl pep-
tidase-4 (DPP-4) inhibitor (63.6 vs. 48.9%,
respectively), or a sodium-glucose cotransporter
2 inhibitor (8.5 vs. 1.2%, respectively). Addi-
tional details on patient demographics and
baseline clinical characteristics in patient sub-
cohorts by number of OADs (1, 2, or C 3) and
Fig. 1 Flow diagram of patient cohort selection. BI basal
insulin, EMR electronic medical record, GLP-1 RA
glucagon-like peptide-1 receptor agonist, HbA1c glycated
hemoglobin, OAD oral antidiabetic drug, T1D type 1
diabetes, T2D type 2 diabetes
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Mean (SD) 69.9 (13.8) 64.3 (12.4) 59.7 (13.5)
Median 72.2 65.4 60.5
C 65 years, n (%) 196,152 (71.9) 1782 (51.3) 287 (36.8)
Female, n (%) 120,477 (44.2) 1,316 (37.8) 345 (44.2)
HbA1c, %
Mean (SD) 6.5 (1.1)a 9.4 (1.8) 8.8 (1.4)
Median (range) 6.0 (2.4–6.9)a 9.1 (7.0–20.2) 8.5 (7.0–15.8)
HbA1c category
7–\ 8%, n 21,055 745 253
Median (range) 7.3 (7.0–7.9) 7.4 (7.0–7.9) 7.5 (7.0–7.9)
8–\ 9%, n 6758 888 241
Median (range) 8.3 (8.0–8.9) 8.4 (8.0–8.9) 8.4 (8.0–8.9)
C 9%, n 4357 1844 286
Median (range) 9.8 (9.0–18.7) 10.4 (9.0–20.2) 10.0 (9.0–15.8)
Mean (SD) BMIb, kg/m2 23.4 (4.5) 24.1 (4.2) 28.2 (5.8)
Mean (SD) T2D duration, years 7.3 (6.1) 6.5 (6.3) 6.5 (5.9)
Follow-up timec, days (Q1–Q3) NA 720 (622–720) 720 (627–720)
Comorbidityd, n (%)
Hypertension 14,397 (5.3) 2223 (63.9) 571 (73.2)
Dyslipidemia 10,977 (4.0) 2268 (65.2) 603 (77.3)
Obesity 2467 (0.9) 146 (4.2) 111 (14.2)
Renal impairment 4896 (1.8) 391 (11.2) 105 (13.5)
Atherosclerotic cardiovascular disease 25,167 (9.2) 1903 (54.7) 421 (54.0)
Number of OADs, n (%)
1 216,636 (79.4) 1114 (32.0) 194 (24.9)
2 25,329 (9.3) 1127 (32.4) 250 (32.1)
C 3 17,698 (6.5) 1236 (35.5) 336 (43.1)
Prescription of OAD, n (%)
Metformin 22,468 (8.2) 1352 (38.9) 439 (56.3)
Sulfonylureas 13,031 (4.8) 2164 (62.2) 428 (54.9)
DPP-4 inhibitors 41,647 (15.3) 1701 (48.9) 496 (63.6)
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baseline HbA1c (7 to\8%, 8 to\9%, or C 9%)
within the BI and GLP-1 RA cohorts are shown
in ESM Tables S2 and S3.
HbA1c Change Over Time
Distributions of HbA1c values from 6 months
before to 24 months after initiation of BI or
GLP-1 RA therapy are shown in Fig. 2. For both
cohorts, mean HbA1c levels tended to be higher
during the 3 months prior to the index date,
followed by a rapid decrease within 2–4 months
post index date, without further improvement
thereafter.
HbA1c change from baseline by quarter (3-
month time intervals) after the initiation of BI
or GLP-1 RA therapy are shown in ESM Table S4.
For both cohorts, mean (SD) HbA1c reduction
from baseline peaked at 3–6 months following
initiation, at - 1.85% (2.03%) for BI and
- 1.26% (1.64%) for GLP-1 RA.
Cumulative Probability of Patients
Achieving Glycemic Control
The Kaplan–Meier curves for the cumulative
probability of patients reaching their first
HbA1c\ 7% over time showed similar trends in
the BI and GLP-1 RA cohorts (Fig. 3a, b), with a
sharp increase in probability within 6 months
following the initiation of BI or GLP-1 RA
therapy and only a slight increase thereafter. In
the BI cohort, approximately 28.6, 40.7, 50.1,
and 60.3% of patients achieved their first HbA1c
\7% within 3, 6, 12, and 24 months, respec-
tively; these proportions were 39.5, 50.9, 60.8,
and 66.6%, respectively, in the GLP-1 RA
cohort.
In both the BI and GLP-1 RA cohorts,
patients taking greater numbers of OADs at
baseline showed a lower cumulative probability
of achieving their first HbA1c\7% throughout
the 24-month follow-up period (Fig. 3c, d). For
both the BI and GLP-1 RA cohorts, differences
between subcohorts by number of OADs at
baseline were significant according to log-rank
test (P\0.05 for all pair-wise comparisons
between subcohorts). In both cohorts, the sub-
cohorts of patients with baseline HbA1c C 9%
had the lowest cumulative probability of
achieving glycemic control, while those with
HbA1c 7–\8% had the highest probability
(Fig. 3e, f); all pair-wise comparisons between
subcohorts showed significant differences








TZDs 4811 (1.8) 650 (18.7) 129 (16.5)
SGLT-2 inhibitors 6866 (2.5) 42 (1.2) 66 (8.5)
Alpha-GI 10,746 (3.9) 1205 (34.7) 189 (24.2)
Glinide 4936 (1.8) 351 (10.1) 71 (9.1)
Alpha-GI alpha-glucosidase inhibitor, BI basal insulin, BMI body mass index, DPP-4 dipeptidyl peptidase-4, GLP-1 RA
glucagon-like peptide-1 receptor agonist, HbA1c glycated hemoglobin, ICD International Classification of Diseases, NA not
applicable, OAD oral antidiabetic drug, Q1 lower quartile, Q3 upper quartile, SD standard deviation, SGLT-2 sodium-
glucose cotransporter 2, T2D type 2 diabetes, TZD thiazolidinedione
a Data are for HbA1c\ 7%
b n = 589 (BI cohort) and 120 (GLP-1 RA cohort). BMI is available for inpatients only
c Follow-up time for probability of glycemic control analyses (index date to last date of BI or GLP-1 RA prescription)
d Obesity was defined as a BMI C 30 kg/m2 or the presence of ICD-10 codes for obese/morbidly obese; the other
comorbidities were based on ICD-10 codes
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notable differences were observed in the
cumulative probability curves between subco-
horts by age (\ 65 or C 65 years) in either the BI
or the GLP-1 RA cohorts (data not shown).
Estimation of Conditional Probabilities
The proportion of patients who reached their
first HbA1c \7% within the first quarter
(0–3 months post index date) was 20.3% in the
BI cohort and 38.6% in the GLP-1 RA cohort
(Table 2). Among patients who had not reached
HbA1c \7% in the first quarter following the
index date, the probability of reaching first
glycemic control in the second quarter was
17.3% for the BI cohort and 19.0% for the GLP-
1 RA cohort (Table 2). The respective condi-
tional probabilities declined to 8.9% and 9.4%
in the third quarter, and remained at \ 10%
thereafter for both cohorts (other than a 12.9%
probability in the fourth quarter for GLP-1 RA).
DISCUSSION
Based on data in the Japanese RWD database
between January 2010 and June 2019, approxi-
mately fourfold more patients intensified their
OAD therapy with BI compared with GLP-1 RA.
Fig. 2 Monthly HbA1c distributions [mean (SD)] from
6 months before to 24 months after BI or GLP-1 RA
initiation (index date) in the BI cohort (a) and GLP-1 RA
cohort (b). Data are presented as the mean with the
standard deviation (SD). x-axis values correspond to the
start of the time interval assessed (data at month 1
correspond to the time period of 1 month post index date
to\ 2 months post index date). Data were not adjusted
for censorship or achievement of glycemic control
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Initiation of BI or GLP-1 RA therapy occurred at
an advanced stage of disease, after a mean of
6.5 years with T2D and high HbA1c [mean
HbA1c of 9.4% (BI) and 8.8% (GLP-1 RA)], with
over one third of patients taking C 3 OADs. The
delay in treatment intensification, or clinical
Fig. 3 Overall cumulative probability of reaching first
HbA1c \ 7% within 2 years post index date in the BI
cohort (a) and GLP-1 RA cohort (b), and in subcohorts by
number of OADs among the BI cohort (c) or GLP-1 RA
cohort (d) or by HbA1c at baseline among the BI cohort
(e) or GLP-1 RA cohort (f)
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inertia, observed in the present study is consis-
tent with previous real-world studies in Japan,
which found that the mean HbA1c of patients
initiating BI therapy was 9.4% [15, 16]. Simi-
larly, in the DAWN JAPAN survey study, the
mean HbA1c at which insulin therapy was rec-
ommended by physicians was 9.6% [17].
Patients initiating GLP-1 RA therapy tended
to be younger than those intitiating BI therapy,
with a lower mean baseline HbA1c. In addition,
consistent with the benefits of body weight
associated with the GLP-1 RA class, patients
initiating GLP-1 RA therapy had a higher BMI at
baseline than those initiating BI. Observed dif-
ferences in the types of OADs used may reflect
differences in disease pathophysiology between
patients initiating BI versus GLP-1 RA therapies.
The use of sulfonylureas, which are insulin
secretagogues suited for patients with insulin
deficiency, was higher in patients initiating BI
than in those initiating GLP-1 RAs, while met-
formin, which reduces blood glucose at least in
part by improving insulin sensitivity, was used
more frequently in patients initiating GLP-1
RAs compared with those initiating BI. The use
of alpha-glucosidase inhibitors, which delay the
absorption of sugars by inhibiting enzymes,
thereby reducing postprandial hyperglycemia,
was more common among patients initiating BI
than in those initiating GLP-1 RA therapy. DPP-
4 inhibitors, which block the degradation of
endogenous GLP-1 and promote glucose-de-
pendent insulin secretion, were also more
commonly used by patients initiating GLP-1 RA
therapy. However, it is worth noting that about
half of the patients initiating BI therapy were
also being treated with DPP-4 inhibitors, in line
























































[ 0–3 3320 674 20.3 (18.9–21.7) 762 294 38.6 (35.1–42.0)
[ 3–6 1453 251 17.3 (15.3–19.2) 406 77 19.0 (15.2–22.8)
[ 6–9 1087 97 8.9 (7.2–10.6) 299 28 9.4 (6.1–12.7)
[ 9–12 886 72 8.1 (6.3–9.9) 249 32 12.9 (8.7–17.0)
[ 12–15 751 52 6.9 (5.1–8.7) 205 13 6.3 (3.0–9.7)
[ 15–18 647 34 5.3 (3.5–7.0) 177 6 3.4 (0.7–6.1)
[ 18–21 584 36 6.2 (4.2–8.1) 160 6 3.8 (0.8–6.7)
[ 21–24 510 26 5.1 (3.2–7.0) 144 5 3.5 (0.5–6.5)
CI Confidence interval
a Conditional probability is defined as the percentage of patients achieving glycemic control within the specified time
interval, among patients who had not reached glycemic control previously, were still on treatment, and had at least one valid
HbA1c record within the time interval
Diabetes Ther
with the prevalent use of this class of drugs in
Japanese patients with T2D [18].
In patients initiating BI or GLP-1 RA therapy,
HbA1c levels tended to increase rapidly during
the 3 months prior to initiation, which may
have prompted the initiation of injectable ther-
apy. This trend was then followed by a rapid
decrease within 2–4 months of treatment initi-
ation, without further improvement thereafter.
Although there was a sharp increase in the
cumulative probability of reaching HbA1c\ 7%
within 6 months of initiation of BI or GLP-1 RA
therapy, the rates of increase declined over
time. The conditional probability of achieving
HbA1c\7% with BI or GLP-1 RA therapy was
highest in the first 3 months following treat-
ment initiation (20.3% for BI and 38.6% for
GLP-1 RA), then declined thereafter to \ 10%
after 6–12 months. These data are consistent
with the findings from similar retrospective
database studies in the UK [13] and USA [12]
and suggest that for Japanese patients who have
not reached glycemic goals at early stages of BI
or GLP-1 RA treatment, the probability of
achieving the target is low, and early treatment
escalation is warranted. Reports of factors that
might adversely influence the prescribing of
GLP-1 RAs in Japan appear to be limited. How-
ever, it is possible that the injectable nature of
the treatment is a limitation. Furthermore, one
of the perceived advantages of GLP-1 RAs in
Western countries (namely, weight loss) is not a
major clinical objective in Japanese patients
with T2D.
Patients initiating BI or GLP-1 RA therapy
with higher baseline HbA1c or those who were
taking multiple OADs had a lower probability of
achieving HbA1c \ 7% throughout the 2-year
follow-up period compared with those with
lower baseline HbA1c or taking fewer OADs. In
line with the approach of early intensive ther-
apy in patients with high HbA1c, the 2018
ADA/EASD consensus report recommends ini-
tial injectable combination therapy with GLP-1
RA and BI or prandial/BI for patients with
HbA1c [ 10% and/or [2% above target [5].
However, while insulin in combination with a
GLP-1 RA is listed as a treatment option for
patients with inadequate glycemic control, the
current JDS guidelines do not make a
recommendation for any specific combination
to be used as initial injectable therapy [6].
The importance of glycemic control in low-
ering the risk of diabetes complications is
highlighted in the ADA, EASD, and JDS guide-
lines, and the benefits of aggressive glycemic
management have been shown by long-term
studies. The UK Prospective Diabetes Study
demonstrated over 10 years of follow-up that
intensive blood-glucose control substantially
decreases the risk of microvascular complica-
tions in patients with T2D [4]. In a prospective
study in Japan, intensive glycemic control was
associated with a delay in the onset and pro-
gression of diabetic retinopathy, nephropathy,
and neuropathy in patients with T2D [3].
The efficacy and safety of BI and GLP-1 RA
therapies in Japanese patients are well established
in RCTs [19–26]. While RCTs provide a controlled
setting to evaluate the effects of therapeutic
interventions using standardized treatments in a
well-defined patient cohort, they may not neces-
sarily fully reflect the treatment practices and
patient populations seen in real-world practice.
Indeed, there is a gap between the efficacy of
glycemia-lowering agents reported from RCTs
and that reported from real-world studies, with
smaller improvements in HbA1c observed in the
real world [27]. Real-world data may guide indi-
vidualized treatment decisions and provide
important insights into the challenges that are
encountered in routine clinical practice. In our
current real-world database study, initiation of BI
or GLP-1 RA therapy was insufficient to provide
HbA1c control for many Japanese patients
intensifying OAD therapy, highlighting the
unmet need for alternative treatment strategies in
this population.
There are several limitations to this study.
General limitations of observational, non-ran-
domized studies include selection bias and the
inability to confirm efficacy in the absence of a
placebo arm. Nonetheless, real-world data do
provide important insights, as discussed above.
In this study, our data confirm that initiation of
either medication (BI or GLP-1 RA) is considered
only after attempts have been made to optimize
the use of OADs for at least 6 months. While the
large sample size is a strength of the study, the
fact that it included primarily the hospital-
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based cohort is a limitation; patients who were
not part of the participating facilities were not
captured in this study. The database consists of
a limited number of hospitals and clinics and
does not cover all regions of Japan. Further-
more, patients who transferred to other insti-
tutions could not be followed up, and data were
based on prescriptions written; imperfect
adherence could have reduced the effects of
treatment. Persistence data are not currently
available from this study to enable investigation
of this aspect of treatment. The study was orig-
inally designed to compare outcomes between
patients who received BI or GLP-1 RA but not
the other, versus those who received sequential
therapy with BI and GLP-1 RA. However,
because of the low number of patients in the
database with records of sequential therapy,
only the cohort of patients initiating BI or GLP-
1 RA without sequential therapy was analyzed.
Additionally, the treatment options for GLP-1
RAs in Japan were not constant throughout the
study period; for example, lixisenatide was
approved in 2013, and dulaglutide was
approved in 2015. While a 10-year period was
considered, this was not a longitudinal study
and, although it would have been interesting to
investigate how treatment changed over time as
different agents became available or more
widely used, this was outside the scope of this
analysis. Although subgroup analyses were
conducted according to potentially relevant
patient factors, additional unknown con-
founders could exist and contribute to any dif-
ferences between BI and GLP-1 RA cohorts.
CONCLUSIONS
This retrospective, observational study conducted
in Japan demonstrated that in patients with T2D
inadequately controlled on OADs, escalation to BI
or GLP-1 RA therapy occurred after many years of
disease, when HbA1c levels had risen far above
target values, and often after inadequate response
to multiple OADs. Patients who initiated GLP-1
RA therapy tended to be slightly younger and
have higher BMI and lower HbA1c at baseline
compared with those who initiated BI therapy.
The conditional probability of reaching HbA1c
\7% with BI or GLP-1 RA declined over time,
suggesting that treatment intensification should
be considered for patients who do not achieve
their glycemic goal in the first 6–12months on BI
or GLP-1 RA. In particular, patients with high
baseline HbA1c (C 9%) or those on multiple
OADs (C 3) may benefit from early treatment
escalation, based on the low probability of
achieving target HbA1c in these patient popula-
tions. Overall, these results highlight the need for
new treatment strategies to allow more patients
in Japan with T2D inadequately controlled on
OADs to achieve early glycemic control.
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